Intravenous ferric derisomaltose for iron deficiency anemia in pregnancy :- Medznat
EN | RU
EN | RU

Help Support

By clicking the "Submit" button, you accept the terms of the User Agreement, including those related to the processing of your personal data. More about data processing in the Policy.
Back

Intravenous ferric derisomaltose boosts maternal & neonatal outcomes in IDA

Iron deficiency anemia in pregnancy Iron deficiency anemia in pregnancy
Iron deficiency anemia in pregnancy Iron deficiency anemia in pregnancy

What's new?

A single, 24-minute IV infusion of ferric derisomaltose (1000 mg) rapidly elevates maternal hemoglobin levels and enhances infant iron reserves while reducing postpartum depression and fatigue risks.

Iron deficiency anemia (IDA) during pregnancy can compromise maternal well-being and neonatal iron status. Although oral iron is commonly utilized, poor adherence can restrict treatment success, while some intravenous iron formulations require multiple infusions. A study, led by Ashley E. Benson et al., explored whether a single dose of ferric derisomaltose (FDI) yields an effective and convenient alternative during pregnancy.

Conducted between January 2024 and July 2025, the prospective, single-arm interventional trial assessed the safety and efficacy of a single 1,000 mg IV dose of FDI administered during the second or third trimester. The mean infusion duration was 24 minutes. Of the 78 participants enrolled, 75 received treatment. The key endpoint ascertained was a hemoglobin (Hb) increase of at least 1 g/dL. Secondary endpoints included other hematological parameters, patient-reported quality of life, safety, and maternal and neonatal outcomes.

Key findings

  • Improved Hb levels: Mean Hb rose by 1.3 g/dL from baseline to delivery.
  • Enhanced iron status: Serum ferritin and transferrin saturation improved substantially, with benefits sustained through six weeks postpartum.
  • Reduced fatigue and improved well-being: Patient-reported fatigue scores improved significantly. Edinburgh Postnatal Depression Scale (EPDS) scores also noticeably decreased.
  • Potential neonatal benefits: Cord blood ferritin and Hb measurements suggested improved neonatal iron status.
  • Favourable safety profile: No major infusion reactions or hospitalizations were noted.

Minor infusion-linked symptoms were uncommon and self-limited. These encompassed chest tightness (6.7%), flushing (5.3%), mild shortness of breath (4%), urticaria (2.7%) and rash (1.3%). Notably, 2 subjects (2.6%) did not complete the infusion because of an infusion reaction. These results highlight single-dose IV FDA as a valuable option for tackling late-stage maternal IDA, though larger trials remain prudent to confirm comparative superiority.

Source:

American Journal of Hematology

Article:

Efficacy of Single-Dose Intravenous Ferric Derisomaltose for Iron Deficiency Anemia in Pregnancy

Authors:

Ashley E. Benson et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en
Try: